News

Business Insider5y
Turning Point Therapeutics Announces Updated Interim Clinical Data of Repotrectinib and Preclinical Data for TPX-0046, a Novel RET/SRC Inhibitor - Markets Insider
SAN DIEGO, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs to address treatment resistance, today announced ...
Business Insider5y
Turning Point Therapeutics Initiates Phase 1/2 Clinical Study of TPX-0046, a Novel RET/SRC Inhibitor - Markets Insider
SAN DIEGO, Nov. 11, 2019 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drug ...
Nature13y
RET, ROS1 and ALK fusions in lung cancer | Nature Medicine
RET split FISH on the tissue arrays identified 22 fusion-positive tumors in 1,528 lung cancers , from which a multiplex RT-PCR system that captures all possible KIF5B-RET fusions detected 12 ...
Business Wire7y
Ignyta Provides Update on Entrectinib and RXDX-105 at the ESMO 2017 Congress - Business Wire
New Phase 1b clinical data on RXDX-105 presented this week at the ESMO 2017 Congress in Madrid, Spain demonstrated clinical activity in RET fusions and compelling response rate in an ultra-rare ...
Seeking Alpha7y
Blueprint Medicines Vs. Loxo Oncology: A Head-To-Head Of Novel RET Inhibitors (NASDAQ:BPMC) - Seeking Alpha
RXDX-105 achieved promising results in non-KIF5B RET fusions with 6/8 patients responding for an ORR of 75%, but came up short in KIF5B fusions with 0/14 patients responding to treatment.
Healio13y
Gene abnormalities identified patients with elevated response to targeted drugs
Gene abnormalities discovered in a subpopulation of lung and colorectal tumors could identify patients with a heightened response to highly specific drugs used for other cancers, according to ...
Business Wire13y
Foundation Medicine and Dana-Farber Cancer Institute Identify Novel Genomic Alterations in Lung and Colorectal Cancer - Business Wire
The novel, recurrent KIF5B-RET fusion was identified by the NGS assay in one patient with NSCLC. In subsequent screening, 11 additional ...
NextBigFuture13y
Gene fusion in lung cancer afflicting never-smokers may be target for therapy
Genome research – Fusion of KIF5B and RET transforming gene in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing Recent strides have been made to identify gene mutation ...
FierceBiotech12y
Exelixis Announces Initiation of Cabozantinib Investigator-Sponsored Trials in Non-Small Cell Lung Cancer and Multiple Myeloma | Fierce Biotech
Investigators will also seek to determine the frequency of KIF5B/RET and related variant RET fusions in patients whose tumors are negative for previously identified oncogenic activating mutations ...
technologynetworks13y
Foundation Medicine and Dana-Farber Cancer Institute Identify Novel Genomic Alterations in Lung and Colorectal Cancer - Technology Networks
Foundation Medicine, Inc. and Dana-Farber Cancer Institute have announced the Nature Medicine publication of results from their collaborative next-generation sequencing (NGS) study to assay ...
FiercePharma12y
Exelixis Announces Initiation of Cabozantinib Investigator-Sponsored Trials in Non-Small Cell Lung Cancer and Multiple Myeloma - Fierce Pharma
Exelixis, Inc. (NASDAQ:EXEL) today announced the initiation of two investigator-sponsored trials (ISTs) of cabozantinib, which simultaneously targets MET, VEGFR2 and RET. Naiyer Rizvi, M.D., a ...